Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Silence Therapeutics PLC

www.silence-therapeutics.com

Latest From Silence Therapeutics PLC

Interview: Alnylam President On Patisiran Lift-Off Plans

Barry Greene, president of Alnylam, tells Scrip that the company is happy to consider risk-sharing with payers, as the firm is confident about the 'extreme value' that its RNAi therapeutic for hATTR amyloidosis will offer, if approved.

Companies Commercial

Silence Seeks Share Of Alnylam RNAi Success In Legal Action

The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.

Intellectual Property Commercial

Appointments: BMS, Scancell, Zafgen, Cell Medica, Silence Therapeutics, Malin and Trillium

This week's roundup includes CEO appointments by Gadeta, Scancell and Zafgen, with various other high-level appointments by Malin Corporation, Cell Medica and Apeiron Biologics.

Appointments BioPharmaceutical

Appointments: GSK, Neurocrine Biosciences, Cue Biopharma, BenevolentAI And Ferring Pharmaceuticals

This week's roundup includes two executive appointments by GSK, plus updates from Radius Health Inc., Cue Biopharma and BenevolentAI, with Myovant Sciences making four key management hires.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • SR Pharma PLC
  • Stanford Rook Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Silence Therapeutics PLC
  • Senior Management
  • Ali Mortazavi, PhD, CEO
    Timothy Freeborn, Fin. Dir. & Secretary
    Jorg Kaufmann, PhD, CSO
  • Contact Info
  • Silence Therapeutics PLC
    Phone: (44) (0)20 3700 9711
    1 Lyric Square
    London, W6 0NB
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register